General description

A cell-permeable aryl-hydroxamate compound that selectively inhibits the activity of HDAC8 (IC₅₀ = 14 µM) over class I HDAC1 and class II HDAC6 (IC₅₀ >100 µM) without affecting the overall H4 acetylation level in BE(2)-C cultures even at concentrations as high as 20 µM. HDAC8 downregulation by either Compound 2 (10 to 40 µM) or siRNA in neuroblastoma cultures is reported to result in growth inhibition accompanied by neurite-like morphological changes. Compound 2 effectively enhances tubulin acetylation in both HeLa and HEK 293 cultures, indicating that alternative cellular enzyme(s) other than HDAC6 can be targeted for regulating tubulin acetylation.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Oehme, I., et al. 2009. Expert Opin. Investig. Drugs18, 1605.Oehme, I., et al. 2009. Clin. Cancer Res.15, 91.KrennHrubec, K., et al. 2007. Bioorg. Med. Chem. Lett.17, 2874.

Packaging

Packaged under inert gas

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Warning

Toxicity: Standard Handling (A)